Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?

Group 1 - MeiraGTx Holdings PLC (MGTX) shares increased by 6.2% to close at $8.09, supported by higher trading volume compared to normal sessions [1] - The company reported strong financial results for Q4 and full-year 2025, and received FDA Breakthrough Therapy designation for AAV2-hAQP1, which may have contributed to the share price increase [2] - The upcoming quarterly loss is expected to be $0.62 per share, a year-over-year decline of 21.6%, while revenues are projected at $3.41 million, reflecting a 76.7% increase from the previous year [3] Group 2 - The consensus EPS estimate for MeiraGTx has been revised down by 5.6% over the last 30 days, indicating a negative trend in earnings estimate revisions [4] - MeiraGTx holds a Zacks Rank of 3 (Hold), while another company in the same industry, CorMedix (CRMD), has a Zacks Rank of 4 (Sell) and experienced a 2.1% decline in its last trading session [5] - CorMedix's EPS estimate has decreased by 38.5% over the past month, although it represents a year-over-year increase of 53.3% [6]